Skip to main content
RT @drdavidliew: I was schooled for exams, testing fine motor function with a buttonhole: felt contrived.

Imagine an el

David Liew drdavidliew

3 years 10 months ago
I was schooled for exams, testing fine motor function with a buttonhole: felt contrived. Imagine an electrical glove for RA pts, doing functional assessment properly Italian study: engineered glove data + HAQ correlates with DAS28 Consistent/scalable! ABST0904 #ACR22 @RheumNow https://t.co/4ZR0An5N9j
RT @RichardPAConway: Martínez-López et al. Higher rates of elevated transaminases with DMARD in those who previously h

Richard Conway RichardPAConway

3 years 10 months ago
Martínez-López et al. Higher rates of elevated transaminases with DMARD in those who previously had abnormal transaminases with isoniazid. @RheumNow #ACR22 Abstr#0816 https://t.co/xiL6DPPcw3 https://t.co/jjxRoEr8iM
RT @RichardPAConway: Khidir et al. Lower educational level increases risk of progression of clinical suspect arthralgia

Richard Conway RichardPAConway

3 years 10 months ago
Khidir et al. Lower educational level increases risk of progression of clinical suspect arthralgia to inflammatory arthritis. HR 2.35 and 5.72 in 2 cohorts. not explained by smoking, BMI or a delay in seeking medical care @RheumNow #ACR22 Abstr#0704 https://t.co/B4bm2Ihapx https://t.co/Veks0WpHLR
RT @ericdeinmd: Ab1042 #ACR22 Ixekizumab Long-term Safety
A Deodhar: Pooled 25 studies for PsO, PsA, AS

5.4 pooled AE p

Eric Dein ericdeinmd

3 years 10 months ago
Ab1042 #ACR22 Ixekizumab Long-term Safety A Deodhar: Pooled 25 studies for PsO, PsA, AS 5.4 pooled AE per 100-patient/year 0.5 IBD per 100-PY 1.3 Oral candidiasis per 100-PY Re-assuring safety numbers. Deodhar: "These are numbers to use in clinical practice" @RheumNow
Data presented at ACR22 shows that cycling through TNFi in axSpA patients with primary lack of efficacy with first line TNFi has limited additional benefit in controlling disease. 
RT @RichardPAConway: Hamroun et al. Unfavourable pregnancy outcomes associated age, nulliparity, steroids in RA. Can onl

Richard Conway RichardPAConway

3 years 10 months ago
Hamroun et al. Unfavourable pregnancy outcomes associated age, nulliparity, steroids in RA. Can only modulate the final one! @RheumNow #ACR22 Abstr#0955 https://t.co/Vob1GeMN25 https://t.co/CsVshIzp8a
RT @AurelieRheumo: de Hooge & al: parameters assoc w/ risk of developing syndesmophytes at 2 yrs in PsA:

Radiograph

Aurelie Najm AurelieRheumo

3 years 10 months ago
de Hooge & al: parameters assoc w/ risk of developing syndesmophytes at 2 yrs in PsA: Radiographic SI according to mNY = 30x higher risk If Rx SI + CRP>6 = 100% risk devlpmt syndesmophytes @ 2 yrs. https://t.co/CR0LymrQdr Abs#1014 #ACR22 @Rheumnow #ACRBest https://t.co/TLWYCJ0eYi
RT @RichardPAConway: Rouhi @Janetbirdope et al RS3PE post checkpoint inhibitor. 11 cases. Can flare after checkpoint inh

Richard Conway RichardPAConway

3 years 10 months ago
Rouhi @Janetbirdope et al RS3PE post checkpoint inhibitor. 11 cases. Can flare after checkpoint inhibitor reintroduction and occur following treatment. @RheumNow #ACR22 Abstr#0758 https://t.co/KCzdJvD0da https://t.co/WQ4eB2hz1k
RT @AurelieRheumo: Giblo et al, 1000+ pop-based cohort RA:

Cumulative incidence of depression =
Increase in cumulative

Aurelie Najm AurelieRheumo

3 years 10 months ago
Giblo et al, 1000+ pop-based cohort RA: Cumulative incidence of depression = Increase in cumulative incidence of anxiety 2005–14 vs. earlier decades Despite improvements in RA ttmts. Maybe time we address these separately? https://t.co/Z3FUgSETKW Abs#0889 #ACR22 @Rheumnow https://t.co/Rn2ru80021
RT @RichardPAConway: Kang @karen_kc123 et al ≥ 20 pack-years cigarette smoking associated with higher risk of inciden

Richard Conway RichardPAConway

3 years 10 months ago
Kang @karen_kc123 et al ≥ 20 pack-years cigarette smoking associated with higher risk of incident PMR in women (HR 1.46). Every 10 pack-years associated 9% increase in risk @RheumNow #ACR22 Abstr#0698 https://t.co/t51fKFs7iJ https://t.co/IS9XC9DXl8
RT @RichardPAConway: Maguire @Sineadm15 @rheum_covid (and me!) obstetric outcomes in RMD and COVID-19. Unvaccinated high

Richard Conway RichardPAConway

3 years 10 months ago
Maguire @Sineadm15 @rheum_covid (and me!) obstetric outcomes in RMD and COVID-19. Unvaccinated higher freq pre-term birth. Regardless of vaccine status, the women themselves did well, rarely needing pharmacotherapy @RheumNow #ACR22 Abstr#0950 #ACRbest https://t.co/GLMAAvbC4a https://t.co/kpXZbRSoMo
RT @AurelieRheumo: DIPSA: RCT in PsA pts w/ BMI > 25 Mediterranean diet vs. DASH-low caloric diet vs. SoC
BL: 72% obe

Aurelie Najm AurelieRheumo

3 years 10 months ago
DIPSA: RCT in PsA pts w/ BMI > 25 Mediterranean diet vs. DASH-low caloric diet vs. SoC BL: 72% obese, 42% dyslipidemia, 38% HBP, MetS 47% Looking forward to seeing the results of this dietary intervention, MetS is high in PsA! https://t.co/29Aq0TLANO Abs#1007 #ACR22 @Rheumnow https://t.co/MoVYnQV6xR
RT @ericdeinmd: Ab0411 #ACR22 Bimekizumab in AS
P3 24 wk PBO control study BE-MOBILE 2

221 BKZ, 111 PBO
Wk 16 ASAS40: B

Eric Dein ericdeinmd

3 years 10 months ago
Ab0411 #ACR22 Bimekizumab in AS P3 24 wk PBO control study BE-MOBILE 2 221 BKZ, 111 PBO Wk 16 ASAS40: BKZ 45%, 22% PBO p<0.001 Efficacy in both TNF naive and TNF failure pts Wk 24: 1/2 pts has ASDAS<2.1 Nasopharyngitis (6%), diarrhea (4%), h/a (3.6%) 👅candidiasis (3%) @Rheumnow https://t.co/R1ieW0FB6m
RT @RichardPAConway: Mathew et al. Combination biologics from MarketScan. Combination less likely to have ER visit in 18

Richard Conway RichardPAConway

3 years 10 months ago
Mathew et al. Combination biologics from MarketScan. Combination less likely to have ER visit in 180 days 17% vs 23% @RheumNow #ACR22 Abstr#0768 https://t.co/Y880qDXMow https://t.co/gOH2Zlt6UV
RT @AurelieRheumo: CASIPSA study: retro CT SIJ analysis 48 PsA &amp; age/sex matched ctrls.
JSN, erosion, sclerosis in 1

Aurelie Najm AurelieRheumo

3 years 10 months ago
CASIPSA study: retro CT SIJ analysis 48 PsA & age/sex matched ctrls. JSN, erosion, sclerosis in 1/3 pts w/ peripheral & 1/3 pts w/ axial disease. PsA > erosions, no diff in other parameters: lack of power or true absence of diff? https://t.co/CR0LymrinT Abs#1012 #ACR22 @Rheumnow https://t.co/akYYqbIFNx
×